Managing dentine erosion with silver diamine fluoride: An in situ study
Abstract
Objectives: To evaluate anti-erosive effect and associated color change (ΔE00) of 38% silver diamine fluoride (SDF) on human dentine.
Methods: A crossover in situ study involving 15 volunteers was conducted. Participants wore an intra-oral appliance carrying four dentine blocks for three 14-day treatment phases, separated by a 7-day washout period. Three treatments included weekly application of 38% SDF (255,000 ppmAg and 44,800 ppmF, Group SDF), daily application of stannous chloride/amine fluoride/sodium fluoride (800 ppmSn and 500 ppmF, Group SNF), and daily application of deionized water (Group DW). Appliances with dentine blocks were exposed to citric acid (pH 3.2), five daily extraoral erosive challenges. Dentine blocks were assessed for percentage surface microhardness loss (%SMHL), dentine loss, salivary pellicle morphology, crystal characteristics, dentine surface morphology, elemental composition, and ΔE00 by a microhardness tester, optical profilometry, atomic force microscopy (AFM), X-ray diffraction (XRD), scanning electron microscopy (SEM), energy-dispersive X-ray spectroscopy (EDS), and spectrophotometry, respectively.
Results: %SMHL of the experimental groups were SDF:23.3 ± 2.4, SNF:30.2 ± 2.0 and DW:42.4 ± 2.2 (SDF00: SDF 14.8 ± 2.4, SNF 8.1 ± 2.2, DW 4.8 ± 2.3 (SDF>SNF>DW; p < 0.001).
Conclusion: Weekly application of 38% SDF demonstrated significantly better anti-erosive protection but caused black staining on dentine surfaces.
Clinical significance: SDF…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 15 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.